Zerva acquires Acer Therapeutics to bolster rare disease portfolio
The $15m acquisition would give Zerva rights to Acer’s FDA-approved rare Urea cycle disorders drug Olpruva.
The $15m acquisition would give Zerva rights to Acer’s FDA-approved rare Urea cycle disorders drug Olpruva.
What's Your Reaction?
